Checkpoint Kinase Modulation Therapy targets the ATM (Ataxia-Telangiectasia Mutated) and ATR (ATM and Rad3-related) DNA damage checkpoint signaling pathways to prevent excessive neuronal apoptosis while maintaining DNA repair capacity. This therapy addresses the fundamental paradox in neurodegeneration: neurons with elevated DNA damage activate pro-apoptotic checkpoint signaling that accelerates cell death.
Mechanism of Action
Primary Targets
...
Overview
Mermaid diagram (expand to render)
Checkpoint Kinase Modulation Therapy targets the ATM (Ataxia-Telangiectasia Mutated) and ATR (ATM and Rad3-related) DNA damage checkpoint signaling pathways to prevent excessive neuronal apoptosis while maintaining DNA repair capacity. This therapy addresses the fundamental paradox in neurodegeneration: neurons with elevated DNA damage activate pro-apoptotic checkpoint signaling that accelerates cell death.
Mechanism of Action
Primary Targets
ATM (Ataxia-Telangiectasia Mutated)
Central DNA damage sensor kinase
Activated by double-strand breaks
Triggers p53-mediated apoptosis when overactivated
ATM hyperactivation contributes to neuronal loss in AD and PD
ATR (ATM and Rad3-related)
Primary sensor for replication stress
Activated by single-strand DNA
Chk1 phosphorylation leads to cell cycle re-entry
Aberrant cell cycle re-entry is a key contributor to neurodegeneration
Chk2 (Checkpoint Kinase 2)
Downstream effector of ATM
Phosphorylates p53, FOXO3a
Mediates mitochondrial apoptosis pathway
Elevated in AD brains
Therapeutic Strategy
The approach uses selective checkpoint kinase modulators to:
Tone down excessive checkpoint activation - Prevent overzealous DNA damage signaling that triggers apoptosis
Preserve essential DNA repair - Maintain baseline repair capacity
Shift checkpoint equilibrium toward survival - Favor repair over elimination
| Dimension | Score | Rationale | |-----------|-------|-----------| | Novelty | 7 | Checkpoint kinase modulation is underexplored in neurodegeneration | | Mechanistic Rationale | 8 | Clear DNA damage-checkpoint-apoptosis pathway | | Root-Cause Coverage | 7 | Addresses DNA damage accumulation, a root cause | | Delivery Feasibility | 7 | CNS-penetrant small molecules available | | Safety Plausibility | 6 | Checkpoint inhibitors have oncology safety data | | Combinability | 8 | Synergizes with NAD+/SIRT1 approaches | | Biomarker Availability | 8 | Multiple validated biomarkers available | | De-risking Path | 7 | Preclinical validation, oncology repurposing | | Multi-disease Potential | 7 | AD, PD, ALS, FTD, aging | | Patient Impact | 7 | Addresses fundamental neuronal vulnerability | | Total | 72 | |
References
[Yang et al., ATM deficiency results in progressive neuromuscular coordination deficits and neurodegeneration (2015)](https://pubmed.ncbi.nlm.nih.gov/25859008/)
[de Freitas et al., ATM deficiency in neural stem cells accelerates neurogenesis and cognitive decline (2015)](https://pubmed.ncbi.nlm.nih.gov/26299568/)